2024-11-01 2025-10-31 2025-10-31 false 12263031 BRISGAL LIMITED 86210General medical practice activities iso4217:GBP xbrli:pure 122630312024-11-01 122630312025-10-31 122630312024-11-01 2025-10-31 12263031bus:SmallEntities2024-11-01 2025-10-31 12263031bus:AuditExempt-NoAccountantsReport2024-11-01 2025-10-31 12263031bus:FullAccounts2024-11-01 2025-10-31 12263031core:WithinOneYear2025-10-31 12263031core:AfterOneYear2025-10-31 12263031core:WithinOneYear2024-11-01 2025-10-31 12263031core:AfterOneYear2024-11-01 2025-10-31 12263031core:CurrentFinancialInstruments2025-10-31 12263031core:Non-currentFinancialInstruments2025-10-31 12263031core:CurrentFinancialInstruments2024-11-01 2025-10-31 12263031core:Non-currentFinancialInstruments2024-11-01 2025-10-31 12263031core:LandBuildings2024-11-01 2025-10-31 12263031core:FurnitureFittings2024-11-01 2025-10-31 12263031core:OfficeEquipment2024-11-01 2025-10-31 12263031core:Vehicles2024-11-01 2025-10-31 12263031core:PlantMachinery2024-11-01 2025-10-31 12263031core:OtherPropertyPlantEquipment2024-11-01 2025-10-31 12263031core:LandBuildings2025-10-31 12263031core:PlantMachinery2025-10-31 12263031core:Vehicles2025-10-31 12263031core:FurnitureFittings2025-10-31 12263031core:OfficeEquipment2025-10-31 12263031core:OtherPropertyPlantEquipment2025-10-31 12263031core:Right-of-useAssets2024-11-01 2025-10-31 12263031core:Right-of-useAssets2025-10-31 12263031core:Goodwill2024-11-01 2025-10-31 12263031core:PatentsTrademarksLicencesConcessionsSimilar2024-11-01 2025-10-31 12263031core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-11-01 2025-10-31 12263031core:OtherResidualIntangibleAssets2024-11-01 2025-10-31 12263031core:Goodwill2025-10-31 12263031core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-10-31 12263031core:PatentsTrademarksLicencesConcessionsSimilar2025-10-31 12263031core:OtherResidualIntangibleAssets2025-10-31 12263031dpl:CostSales2024-11-01 2025-10-31 12263031dpl:AdministrativeExpenses2024-11-01 2025-10-31 12263031dpl:DistributionCosts2024-11-01 2025-10-3112263031core:ShareCapital2025-10-31 12263031core:SharePremium2025-10-31 12263031core:RevaluationReserve2025-10-31 12263031core:OtherReservesSubtotal2025-10-31 12263031core:ShareCapitalPreferenceShares2025-10-31 12263031core:CapitalRedemptionReserve2025-10-31 12263031core:OtherCapitalReserve2025-10-31 12263031core:RetainedEarningsAccumulatedLosses2025-10-3112263031core:ShareCapital2024-11-01 2025-10-31 12263031core:SharePremium2024-11-01 2025-10-31 12263031core:RevaluationReserve2024-11-01 2025-10-31 12263031core:OtherReservesSubtotal2024-11-01 2025-10-31 12263031core:RetainedEarningsAccumulatedLosses2024-11-01 2025-10-311226303112024-11-01 2025-10-31 1226303122024-11-01 2025-10-3112263031core:ShareCapital12024-11-01 2025-10-31 12263031core:ShareCapital22024-11-01 2025-10-3112263031core:SharePremium12024-11-01 2025-10-31 12263031core:SharePremium22024-11-01 2025-10-3112263031core:RevaluationReserve12024-11-01 2025-10-31 12263031core:RevaluationReserve22024-11-01 2025-10-3112263031core:RetainedEarningsAccumulatedLosses12024-11-01 2025-10-31 12263031core:RetainedEarningsAccumulatedLosses22024-11-01 2025-10-311226303112024-11-01 2025-10-3112263031core:Non-currentFinancialInstrumentscore:CostValuation2024-11-01 12263031core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-10-31 12263031core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-10-31 12263031core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-10-31 12263031core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-10-31 12263031core:Non-currentFinancialInstrumentscore:CostValuation2025-10-3112263031core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2024-11-01 12263031core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-10-31 12263031core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-10-31 12263031core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-10-31 12263031core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-10-31 12263031core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-10-31 12263031core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-10-3112263031core:Non-currentFinancialInstruments2025-10-31 12263031core:Non-currentFinancialInstruments2024-10-31122630312023-11-01 122630312024-10-31 122630312023-11-01 2024-10-31 12263031core:WithinOneYear2024-10-31 12263031core:AfterOneYear2024-10-31 12263031core:CurrentFinancialInstruments2024-10-31 12263031core:Non-currentFinancialInstruments2024-10-31 12263031core:LandBuildings2024-10-31 12263031core:PlantMachinery2024-10-31 12263031core:Vehicles2024-10-31 12263031core:FurnitureFittings2024-10-31 12263031core:OfficeEquipment2024-10-31 12263031core:OtherPropertyPlantEquipment2024-10-31 12263031core:Right-of-useAssets2024-10-31 12263031core:Goodwill2024-10-31 12263031core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-10-31 12263031core:PatentsTrademarksLicencesConcessionsSimilar2024-10-31 12263031core:OtherResidualIntangibleAssets2024-10-31 12263031dpl:AdministrativeExpenses2023-11-01 2024-10-3112263031core:ShareCapital2024-10-31 12263031core:SharePremium2024-10-31 12263031core:RevaluationReserve2024-10-31 12263031core:OtherReservesSubtotal2024-10-31 12263031core:ShareCapitalPreferenceShares2024-10-31 12263031core:CapitalRedemptionReserve2024-10-31 12263031core:OtherCapitalReserve2024-10-31 12263031core:RetainedEarningsAccumulatedLosses2024-10-3112263031core:RetainedEarningsAccumulatedLosses2023-11-01 12263031core:ShareCapital2023-11-01 12263031core:SharePremium2023-11-01 12263031core:RevaluationReserve2023-11-01 12263031core:ShareCapital2023-11-01 2024-10-31 12263031core:SharePremium2023-11-01 2024-10-31 12263031core:RevaluationReserve2023-11-01 2024-10-31 12263031core:OtherReservesSubtotal2023-11-01 2024-10-31 12263031core:RetainedEarningsAccumulatedLosses2023-11-01 2024-10-3112263031bus:Director12024-11-01 2025-10-3112263031bus:Director22024-11-01 2025-10-3112263031bus:PrivateLimitedCompanyLtd2024-11-01 2025-10-31
BRISGAL LIMITED
Unaudited Financial Statements
for the year ended 31 October 2025
Company registration number 12263031
(England and Wales)

Company Information

For the year ended 31 October 2025
Directors Rayner, Brian
Rayner, Amanda

Registered office 10 Mandeville Court
Keinton Mandeville
Somerset
TA11 6FJ

Registered number 12263031

Accountant Blue Lias Accounting Limited
Walker House
Market Place
Somerton
Somerset
TA11 7LX

Statement of Financial Position

As at 31 October 2025
Notes
2025
2024
£
£
£
£
Fixed assets
Tangible assets
4
8,932
12,511
8,932
12,511
Current assets
Debtors
5
4,066
3,630
Cash at bank and in hand
6
1,651
2,799
5,717
6,429
Creditors
Amounts falling due within one year
7
(5,595)
(6,310)
(5,595)
(6,310)
Net current assets (liabilities)
122
119
Total assets less current liabilities
9,054
12,630
Creditors
Amounts falling due after one year
8
(2,778)
(6,469)
(2,778)
(6,469)
Net assets (liabilities)
6,276
6,161
Capital and reserves
Called up share capital
9
1
1
Profit and loss account
6,275
6,160
Total equity
6,276
6,161

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 24 May 2026 and are signed on its behalf by:

Rayner, Brian
Rayner, Brian
Director

Company registration number 12263031

Notes to the Financial Statements

For the year ended 31 October 2025

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.

2.3. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.


Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.


Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.4. Finance leases and hire purchase agreements

Finance leases

Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.

Lease incentives

Incentives received to enter into a finance lease reduce the fair value of the asset and are included in the calculation of present value of minimum lease payments. Incentives received to enter into an operating lease are credited to the profit and loss account, to reduce the lease expense, on a straight-line basis over the period of the lease.

2.5. Current taxation

Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income.


Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.

2.6. Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Rate
Method
%
Motor vehicles
25
Reducing balance
Office and computer equipment
20
Straight-line

2.7. Trade and other debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

2.8. Trade and other creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2.9. Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

3. Employees

The average number of employees during the year was 0 (2024: 0).

4. Tangible fixed assets

Plant and machinery
Motor vehicles
Office equipment
Total
£
£
£
£
Cost
At 1 November 2024
10,528
17,280
1,367
29,175
Additions
469
-
-
469
At 31 October 2025
10,997
17,280
1,367
29,644
Depreciation and impairment
At 1 November 2024
5,109
10,719
836
16,664
Charge for the period
2,200
1,640
208
4,048
At 31 October 2025
7,309
12,359
1,044
20,712
Net book value
At 31 October 2025
3,688
4,921
323
8,932
At 31 October 2024
5,419
6,561
531
12,511

5. Debtors

2025
2024
£
£
Payments on account
595
355
Other debtors
2,316
2,640
Prepayments and accrued income
1,155
635
Total due within one year
4,066
3,630
Total due after one year
-
-
Total
4,066
3,630

6. Cash at bank and in hand

2025
2024
£
£
Cash at bank
1,651
2,799
Total
1,651
2,799

7. Creditors due within one year

2025
2024
£
£
Other creditors
(336)
-
Directors loan account
4,699
5,438
Taxation and social security
302
(148)
Accruals and deferred income
930
1,020
Total
5,595
6,310

8. Creditors due after one year

2025
2024
£
£
Bank loans and overdrafts
2,778
6,469
Total
2,778
6,469

9. Share capital

2025
2024
£
£
Allotted, called up and fully paid
Ordinary Shares
1
1
Total
1
1